2026 Clinical Research Disease 
Advarra
AUGUST 8, 2024
The EU AI Act’s implications extend into clinical research, where AI is increasingly utilized for tasks like medical image analysis, natural language process for endpoint analysis, and generating/analyzing data for synthetic control arms. Non-EU companies must comply with the AI Act if their AI systems are used in the EU market.
Drug Discovery World
JULY 1, 2024
Following a trip to Copenhagen, Denmark, DDW’s Megan Thomas reflects on the Novo Nordisk Foundation’s efforts to tackle cardiometabolic diseases. The World Health Organization (WHO) reports that cardiovascular diseases (CVDs) are the leading cause of death globally, stating that an estimated 17.9 million).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
FEBRUARY 26, 2024
Cell therapies have emerged as transformative and potentially curative treatments across a range of disease areas. She and bit.bio are going beyond this cell type and looking at producing other cell types which may provide answers to a range of diseases beyond blood cancers.
The Pharma Data
NOVEMBER 11, 2020
About Sequana Medical Sequana Medical is a commercial stage medical device company developing the alfa pump platform for the management of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. and EU5 by 2026. GHENT, Belgium, Nov.
The Pharma Data
DECEMBER 16, 2020
About Sequana Medical Sequana Medical is a commercial stage medical device company developing the alfa pump platform for the management of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. and EU5 by 2026. GHENT, Belgium, Dec.
The Pharma Data
OCTOBER 14, 2020
15, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV ( Euronext Brussels: SEQUA ) , an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointments of Dr. Michael Felker and Dr. James Udelson as new Heart Failure Scientific Advisors. and EU5 by 2026.
Agency IQ
APRIL 8, 2024
The FDA created a parallel tool, called the eSubmitter which worked like the SRP with the caveat that case information was not uploaded to FAERS but to the Vaccine Adverse Event Reporting System (VAERS), a program co-monitored by both the FDA and the Centers for Disease Control and Prevention (CDC). database-to-database submissions).
Expert insights. Personalized for you.
52 
Let's personalize your content